Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report
文献类型：期刊论文
| 作者 | Zhou, Qinfei1,2; Zhao, Jiazheng2,3; Wang, Jie4; Bao, Guanai2,5; Gong, Li-Yan1,2 |
| 刊名 | ANNALS OF PALLIATIVE MEDICINE
 |
| 出版日期 | 2020-07-01 |
| 卷号 | 9 |
| 关键词 | Small-cell lung cancer (SCLC) immunotherapy durvalumab third-line treatment case report |
| ISSN号 | 2224-5820 |
| DOI | 10.21037/apm-20-1244 |
| 通讯作者 | Gong, Li-Yan(susang409@hotmail.com) |
| 英文摘要 | The global incidence and mortality rates of lung cancer are the highest of any cancer. Small-cell lung cancer (SCLC) is an undifferentiated carcinoma which accounts for 15-20% of all lung cancers. Compared with the other major lung cancer type, non-small cell lung cancer, SCLC exhibits worse biological behavior, has a higher degree of malignancy, and develops more rapidly. The majority of SCLC present with extensive-stage disease, and the prognosis for these patients remains poor. Recently, immunotherapy has been demonstrated clinical activity in extensive-stage SCLC (ES-SCLC); however, the efficacy and safety of immunotherapy in ES-SCLC needs further confirmation. Durvalumab, a selective, high-affinity human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, showed durable clinical activity and a manageable safety profile in patients with pretreated ES-SCLC as a first-line treatment. Here, we report the case of an ES-SCLC patient who achieved complete remission (CR) of local lesions after receiving durvalumab monotherapy as a third-line treatment, experiencing no obvious immune-related side effects, such as rash, diarrhea, fatigue, myelosuppression, or thyroid dysfunction. No immune-related pulmonary or hepatorenal toxicities occurred. The case suggests that immunotherapy can be selected for third-line or multi-line treatment of ES-SCLC, and anti-PD-L1 antibody may be the better choice for patients who have poor performance status (PS) scores. |
| WOS关键词 | CISPLATIN |
| 资助项目 | Zhejiang Provincial Traditional Chinese Medicine Fund[2019ZB018] ; Zhejiang Provincial Medical and Health Scientific and Technical Fund[2020374375] ; Zhejiang Provincial Natural and Science Fund[LY19H290001] |
| WOS研究方向 | Health Care Sciences & Services |
| 语种 | 英语 |
| WOS记录号 | WOS:000555045100119 |
| 出版者 | AME PUBL CO |
| 资助机构 | Zhejiang Provincial Traditional Chinese Medicine Fund ; Zhejiang Provincial Medical and Health Scientific and Technical Fund ; Zhejiang Provincial Natural and Science Fund |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/102919]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Gong, Li-Yan |
| 作者单位 | 1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Rare & Head & Neck Oncol, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med IBMC, 1 East Banshan Rd, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Head & Neck Surg, Hangzhou, Peoples R China 4.Jinhua Guangfu Canc Hosp, Dept Oncol, Jinhua, Zhejiang, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Integrated Chinese Tradit Med & Western Med, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Qinfei,Zhao, Jiazheng,Wang, Jie,et al. Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report[J]. ANNALS OF PALLIATIVE MEDICINE,2020,9. |
| APA | Zhou, Qinfei,Zhao, Jiazheng,Wang, Jie,Bao, Guanai,&Gong, Li-Yan.(2020).Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report.ANNALS OF PALLIATIVE MEDICINE,9. |
| MLA | Zhou, Qinfei,et al."Durvalumab monotherapy as a third-line treatment for extensive-stage small-cell lung cancer: a case report".ANNALS OF PALLIATIVE MEDICINE 9(2020). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。